Senping Cheng
成森平
Senping Cheng is the founder and CEO of Triastek (三迭纪), a pharmaceutical company applying 3D printing technology to drug development . She co-founded the company with chief scientific officer Professor Li Xiaoling, with the idea originating from a conversation between the two . Under her leadership, Triastek has advanced multiple 3D-printed drugs into clinical trials, including a T21 product for ulcerative colitis designed to reduce side effects through lower dosing , and has partnered with Boehringer Ingelheim to explore its MED® 3D printing technology in new drug R&D .
Related coverage: Cheng is also name-cited in pieces on Linear Capital , ZhenFund , Crossing , FreeS Fund , and 暗涌Waves , though these articles are about other subjects.
AI-generated — may contain errors, please verify.
Coverage
Triastek, an Early Yunqi Capital Portfolio Company, Closes New Strategic Funding Round, Launching New Oral Peptide Strategy | Yunqi Capital
Bringing Innovation to Patients, Faster
Yunqi Capital's Back-to-Work Special: 2025 — Talking Confidence with Tech Founders and Partners
The Lunar New Year holiday just past was anything but quiet in the global tech world. DeepSeek — that "mysterious force from the East" — shattered the assumption that top-tier AI performance requires top-tier computing power, reshaping the global AI landscape through a series of technical innovations and planting a seed of confidence for the year of innovation ahead.
How Can a "3D Printer" Boost Productivity in the Pharmaceutical Industry? | The B-Side of Entrepreneurship
Take the hard, meaningful path
"Triastek" Partners with World's Largest Private Pharmaceutical Company: 3D Printing Technology Accelerates New Drug R&D | Yunqi Tech π
Triastek Enters Partnership with Boehringer Ingelheim
What Are We Actually Reviewing When We Talk About "Reviewing"? | Yunjian · Zhengyuan
After the "Cloud Sight" Series Concludes
Two FDA INDs Approved in Two Years: Triastek's Third 3D-Printed Drug Enters Clinical Trials | Yunqi Capital
Enhanced Safety Through Precision Drug Targeting and Delivery
